The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-70 years of age
Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m\^2 (inclusive)
Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
Is willing and able to discontinue all medications used for the treatment of narcolepsy
Is willing and able to adhere to additional protocol requirements
You may not be if
Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
Clareo Health | A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
